Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer
- 30 June 2003
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 56 (4) , 305-312
- https://doi.org/10.1002/pros.10260
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault.Endocrine-Related Cancer, 2002
- Hormone-refractory prostate cancer: a multi-step and multi-event processProstate Cancer and Prostatic Diseases, 2001
- Prognostic Significance of Neuroendocrine Differentiation in Prostate CancerEuropean Urology, 2000
- Neuroendocrine cells in tumour growth of the prostate.Endocrine-Related Cancer, 1999
- Androgen-independent growth is induced by neuropeptides in human prostate cancer cell linesThe Prostate, 1999
- Neuroendocrine differentiation in prostatic carcinomaThe Prostate, 1999
- Neuroendocrine differentiation in prostatic carcinoma: An updateThe Prostate, 1998
- Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancerThe Prostate, 1998
- Bombesin stimulates growth of human prostatic cancer cellsin vitroCancer, 1990
- Gastrin releasing peptide in human neuroendocrine tumoursThe Journal of Pathology, 1985